CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
SBRTradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02454140
NCT02454140N/ACompleted
CompareCT.gov

Phase I Trial of Adaptive Stereotactic Body Radiotherapy (SBRT) Dose Escalation in Pancreatic Cancer

University of California, San Diego·interventional·Posted May 27, 2015·Updated Sep 12, 2025

In Brief

A clinical study evaluating SBRT for Pancreatic Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study is to determine the maximum tolerated dose (MTD) of five fraction stereotactic radiotherapy (SBRT) in pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 27, 2015
Enrollment StartJun 20, 2014
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 11.1 years ago

Interventions

SBRTradiation

Fixed five-fraction stereotactic radiotherapy